Abstract

Significant survival prolongation in HIV-infected patients due to effective antiretroviral therapy is connected with increasing prevalence of chronic non-infective diseases in this population, among them chronic kidney disease. The pathogenesis of kidney disease in the setting of HIV includes conditions specific for HIV infection: direct effect of the virus, stage of immunodeficiency and drug toxicity. Chronic comorbidities, such as diabetes mellitus, hypertension, and hyperlipidemia, are additional significant risk factors of kidney disease. In HIV-infected individuals some distinct features of these conditions are observed, which are partly related to the virus and antiretroviral therapy. The article summarizes the effect of comorbidities on kidney function in HIV-infected persons.

References

• 1. Abrass C.K.: Diabetic nephropathy. Mechanisms of mesangialmatrix expansion. West. J. Med., 1995; 162: 318-321
  Google Scholar
• 2. Balakumar P., Arora M.K., Reddy J., Anand-Srivastava M.B.: Pathophysiologyof diabetic nephropathy: involvement of multifacetedsignalling mechanism. J. Cardiovasc. Pharmacol., 2009; 54: 129-138
  Google Scholar
• 3. Barbaro G.: Metabolic and cardiovascular complications of highlyactive antiretroviral therapy for HIV infection. Curr. HIV Res.,2006; 4: 79-85
  Google Scholar
• 4. Bergersen B.M., Sandvik L., Dunlop O., Birkeland K., Bruun J.N.:Prevalence of hypertension in HIV-positive patients on highly activeretroviral therapy (HAART) compared with HAART-naive and HIV–negative controls: results from a Norwegian study of 721 patients.Eur. J. Clin. Microbiol. Infect. Dis., 2003; 22: 731-736
  Google Scholar
• 5. Bernardino J.I., Mora M., Zamora F.X., Arribas B., Montes M.L.,Pascual-Pareja F., Jose B.S., Pena J.M., Arribas J.R.: Hypertension andisolated office hypertension in HIV-infected patients determinedby ambulatory blood pressure monitoring: prevalence and risk factors.J. Acquir. Immune Defic. Syndr., 2011; 58: 54-59
  Google Scholar
• 6. Bidani A.K., Griffin K.A.: Long-term renal consequences of hypertensionfor normal and diseased kidneys. Curr. Opin. Nephrol.Hypertens., 2002; 11: 73-80
  Google Scholar
• 7. Bidani A.K., Griffin K.A.: Pathophysiology of hypertensive renaldamage: implications for therapy. Hypertension, 2004; 44: 595-601
  Google Scholar
• 8. Brown T.T., Cole S.R., Li X., Kingsley L.A., Palella F.J., Riddler S.A.,Visscher B.R., Margolick J.B., Dobs A.S.: Antiretroviral therapy andthe prevalence and incidence of diabetes mellitus in the MulticenterAIDS Cohort Study. Arch. Intern. Med., 2005; 165: 1179-1184
  Google Scholar
• 9. Brown T.T., Li X., Cole S.R., Kingsley L.A., Palella F.J., Riddler S.A.,Chmiel J.S., Visscher B.R., Margolick J.B., Dobs A.S.: Cumulative exposureto nucleoside analogue reverse transcriptase inhibitors is associatedwith insulin resistance markers in the Multicenter AIDSCohort Study. AIDS, 2005; 19: 1375-1383
  Google Scholar
• 10. Bucher H.C., Richter W., Glass T.R., Magenta L., Wang Q., CavassiniM., Vernazza P., Hirschel B., Weber R., Furrer H., Battegay M.,Bernasconi E.: Small dense lipoproteins, apolipoprotein B, and riskof coronary events in HIV-infected patients on antiretroviral therapy:the Swiss HIV Cohort Study. J. Acquir. Immune Defic. Syndr.,2012; 60: 135-142
  Google Scholar
• 11. Butt A.A., McGinnis K., Rodrigues-Barradas M.C., Crystal S.,Simberkoff M., Goetz M.B, Leaf D., Justice A.C; Veterans Aging CohortStudy: HIV infection and the risk of diabetes mellitus. AIDS,2009; 23: 1227-1234
  Google Scholar
• 12. Capeau J., Bouteloup V., Katlama C., Bastard J.P., Guiyedi V., Salmon-CeronD., Protopopescu C., Leport C., Raffi F., Chene G.: Ten-yeardiabetes incidence in 1046 HIV-infected patients started on a combinationantiretroviral treatment. AIDS, 2012; 26: 303-314
  Google Scholar
• 13. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J.,Cooper D.A.: A syndrome of peripheral lipodystrophy, hyperlipidaemiaand insulin resistance in patients receiving HIV proteaseinhibitors. AIDS, 1998; 12: F51-F58
  Google Scholar
• 14. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., ChisholmD.J., Cooper D.A.: Diagnosis, prediction, and natural course of HIV-1protease-inhibitor-associated lipodystrophy, hyperlipidaemia, anddiabetes mellitus: a cohort study. Lancet, 1999; 353: 2093-2099
  Google Scholar
• 15. DAD Study Group; Friis-Moller N., Reiss P., Sabin C.A., WeberR., Monforte A.D., El-Sadr W, Thiébaut R., De Wit S., Kirk O., FontasE., Law M.G., Phillips A., Lundgren J.D.: Class of antiretroviraldrugs and the risk of myocardial infarction. N. Engl. J. Med., 2007;356: 1723-1735
  Google Scholar
• 16. De Wit S., Sabin C.A., Weber R., Worm S.W., Reiss P., Cazanave C.,El-Sadr W., Monforte Ad., Fontas E., Law M.G., Friis-Moller N., PhillipsA.; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D)study: Incidence and risk factors for new-onset diabetes in HIV-infectedpatients: the Data Collection on Adverse Events of Anti-HIVDrugs (D:A:D) study. Diabetes Care, 2008; 31: 1224-1229
  Google Scholar
• 17. Di Biagio A., Rosso R., Vitale F., Cardinale F., Sormani M.P., SecondoG., Di Stefano L., Viscoli C.: Risk factors for chronic kidneydisease among human immunodeficiency virus-infected patients:A European case control study. Clin. Nephrol., 2011; 75: 518-523
  Google Scholar
• 18. Eron J. Jr., Yeni P., Gathe J. Jr., Estrada V., DeJesus E., StaszewskiS., Lackey P., Katlama C., Young B., Yau L., Sutherland-Phillips D.,Wannamaker P., Vavro C., Patel L., Yeo J., Shaefer M.; KLEAN studyteam: The KLEAN study of fosamprenavir-ritonavir versus lopinavir–ritonavir, each in combination with abacavir-lamivudine, for initialtreatment of HIV infection over 48 weeks: a randomised non-inferioritytrial. Lancet, 2006; 368: 476-482
  Google Scholar
• 19. Feenev E.R., Mallon P.W.: HIV and HAART-associated dyslipidemia.Open Cardiovasc. Med. J., 2011; 5: 49-63
  Google Scholar
• 20. Freedman B.I., Sedor J.R.: Hypertension-associated kidney disease:perhaps no more. J. Am. Soc. Nephrol., 2008; 19: 2047-2051
  Google Scholar
• 21. Fried L.F., Orchard T.J., Kasiske B.L.: Effect of lipid reductionon the progression of renal disease: a meta-analysis. Kidney Int.,2001; 59: 260-269
  Google Scholar
• 22. Gyebi L., Soltani Z., Reisin E.: Lipid nephrotoxicity: new conceptfor an old disease. Curr. Hypertens. Rep., 2012; 14: 177-181
  Google Scholar
• 23. Hicks C.B., Cahn P., Cooper D.A., Walmsley S.L., Katlama C., ClotetB., Lazzarin A., Johnson M.A., Neubacher D., Mayers D., Valdez H.;RESIST investigator group: Durable efficacy of tipranavir-ritonavirin combination with an optimised background regimen of antiretroviraldrugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention inmulti-drug reSistant patients with Tipranavir (RESIST) studies: ananalysis of combined data from two randomised open-label trials.Lancet, 2006; 368: 466-475
  Google Scholar
• 24. Jotwani V., Li Y., Grunfeld C., Choi A.I., Shlipak M.G.: Risk factorsfor ESRD in HIV-infected individuals: traditional and HIV-relatedfactors. Am. J. Kidney Dis., 2012; 59: 628-635
  Google Scholar
• 25. Kes P., Basić-Jukić N., Ljutić D., Brunetta-Gavranić B.: The role ofarterial hypertension in development of chronic renal failure. ActaMed. Croatica, 2011; 65 (suppl. 3): 78-84
  Google Scholar
• 26. Kim P.S., Woods C., Dutcher L., Georgoff P., Rosenberg A., MicanJ.A., Kopp J.B., Smith M.A., Hadigan C.: Increased prevalence ofalbuminuria in HIV-infected adults with diabetes. PLoS One, 2011;6: e24610
  Google Scholar
• 27. Krishnan S., Schouten J.T., Atkinson B., Brown T., Wohl D., McComsey G.A., Glesby M.J., Shikuma C., Haubrich R., Tebas P., CampbellT.B., Jacobson D.L.: Metabolic syndrome before and after initiation ofantiretroviral therapy in treatment-naive HIV-infected individuals.J. Acquir. Immune Defic. Syndr., 2012; 61: 381-389
  Google Scholar
• 28. Krummel T., Bazin D., Faller A.L., Hannedouche T.: Hypertensivenephrosclerosis. Presse Med., 2012; 41: 116-124
  Google Scholar
• 29. Lehmann R., Schleicher E.D.: Molecular mechanism of diabeticnephropathy. Clin. Chim. Acta, 2000; 297: 135-144
  Google Scholar
• 30. Lu C.L., Lin Y.H., Wong W.W., Lin H.H., Ho M.W., Wang N.C., HsiehS.M., Sheng W.H., Hung C.C., Chen M.Y.: Outcomes of switch to atazanavir-containingcombination antiretroviral therapy in HIV-1-infectedpatients with hyperlipidemia. J. Microbiol. Immunol. Infect.,2011; 44: 258-264
  Google Scholar
• 31. Manitius J.: Nefropatia nadciśnieniowa – niektóre poglądy i kontrowersje.Postępy Nauk Med., 2004; 4: 32-34
  Google Scholar
• 32. Meyrier A.: Hypertensive nephrosclerosis. Pathogenesis, diagnosis and management. Saudi J. Kidney Dis. Transpl., 1999; 10: 267-274
  Google Scholar
• 33. Mills A.M., Nelson M., Jayaweera D., Ruxrungtham K., CassettiI., Girard P.M., Workman C., Dierynck I., Sekar V., Abeele C.V., LavreysL.: Once-daily darunavir/ritonavir vs. lopinavir/ritonavir intreatment-naive, HIV-1-infected patients: 96-week analysis. AIDS,2009; 23: 1679-1688
  Google Scholar
• 34. Muntner P., Coresh J., Smith J.C., Eckfeldt J., Klag M.J.: Plasmalipids and risk of developing renal dysfunction: the atherosclerosisrisk in communities study. Kidney Int., 2000; 58: 293-301
  Google Scholar
• 35. Petoumenos K., Worm S. W., Fontas E., Weber R., De Wit S., BruyandM., Reiss P., El-Sadr W., Monforte A.D., Friis-Moller N., LundgrenJ.D., Law M.G.; D:A:D Study Group: Predicting the short-termrisk of diabetes in HIV-positive patients: the Data Collection onAdverse Events of Anti-HIV Drugs (D:A:D) study. J. Int. AIDS Soc.,2012; 15: 17426
  Google Scholar
• 36. Pyram R., Kansara A., Banerji M.A., Loney-Hutchinson L.: Chronickidney disease and diabetes. Maturitas, 2012; 71: 94-103
  Google Scholar
• 37. Rasmussen L.D., Mathiesen E.R., Kronborg G., Pedersen C., GerstoftJ.: Risk of diabetes mellitus in persons with and without HIV:a Danish nationwide population-based cohort study. PLoS One, 2012;7: e44575
  Google Scholar
• 38. Samaras K.: Prevalence and pathogenesis of diabetes mellitusin HIV-1 infection treated with combined antiretroviral therapy. J.Acquir. Immune Defic. Syndr., 2009; 50: 499-505
  Google Scholar
• 39. Schaeffner E.S., Kurth T., Curhan G.C., Glynn R.J., Rexrode K.M.,Baigent C., Buring J.E., Gaziano J.M..: Cholesterol and the risk of renaldysfunction in apparently healthy men. J. Am. Soc. Nephrol.,2003; 14: 2084-2091
  Google Scholar
• 40. Sprinz E., Lazzaretti R.K., Kuhmmer R., Ribeiro J.P.: Dyslipidemiain HIV-infected individuals. Braz. J. Infect. Dis., 2010; 14: 575-588
  Google Scholar
• 41. Strategies for Management of Antiretroviral Therapy (SMART)Study Group, El-Sadr W.M., Lundgren J., Neaton J.D., Gordin F.,Abrams D., Arduino R.C., Babiker A., Burman W., Clumeck N., CohenC.J., Cohn D., Cooper D., Darbyshire J., Emery S. i wsp.: CD4+ count–guided interruption of antiretroviral treatment. N. Engl. J. Med.,2006; 355: 2283-2296
  Google Scholar
• 42. Thiébaut R., El-Sadr W.M., Friis-Moller N., Rickenbach M., ReissP., Monforte A.D., Morfeldt L., Fontas E., Kirk O., De Wit S., CalvoG., Law M.G., Dabis F., Sabin C.A., Lundgren J.D.; Data Collection ofAdverse events of anti-HIV Drugs Study Group: Predictors of hypertensionand changes of blood pressure in HIV-infected patients.Antivir. Ther., 2005; 10: 811-823
  Google Scholar
• 43. Wahba I.M., Mak R.H.: Obesity and obesity-initiated metabolicsyndrome – mechanistic links to chronic kidney disease. Clin. J. Am.Soc. Nephrol., 2007; 2: 550-562
  Google Scholar
• 44. Wilson S.L., Scullard G., Fidler S.J., Weber J.N., Poulter N.R.: Effectsof HIV status and antiretroviral therapy on blood pressure.HIV Med., 2009; 10: 388-394
  Google Scholar

Full text